Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDG1011 in High Risk Myeloid and Lymphoid Neoplasms
NCT03503968Phase 2Terminated
- Sponsor
- Medigene AG
- Start
- Mar 2018
- Primary completion
- Jun 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of MDG1011 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM) (5 arms), sponsored by Medigene AG. Primary endpoints: Adverse Events and Dose Limiting Toxicities at 3 months, Maximum Tolerated Dose and/or Recommended Phase II Dose at 28 days and 2 more. Started Mar 2018; status: terminated.
02
Drugs
MDG1011
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03503968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03503968.